Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) Products under Development by Stage of Development | 8 | 1 |
| Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) Products under Development by Therapy Area | 9 | 1 |
| Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) Products under Development by Indication | 10 | 2 |
| Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) Products under Development by Companies | 14 | 5 |
| Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) Products under Development by Universities/Institutes | 19 | 2 |
| Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) Therapeutics Assessment | 21 | 4 |
| Assessment by Monotherapy/Combination Products | 21 | 1 |
| Assessment by Mechanism of Action | 22 | 1 |
| Assessment by Route of Administration | 23 | 1 |
| Assessment by Molecule Type | 24 | 1 |
| Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) Companies Involved in Therapeutics Development | 25 | 7 |
| AbbVie Inc. | 25 | 1 |
| AstraZeneca Plc | 26 | 1 |
| BeiGene, Ltd. | 27 | 1 |
| Clovis Oncology, Inc. | 28 | 1 |
| Eisai Co., Ltd. | 29 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 30 | 1 |
| Tesaro, Inc. | 31 | 1 |
| Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) Drug Profiles | 32 | 35 |
| ABT-767 Drug Profile | 32 | 1 |
| AZ-0108 Drug Profile | 33 | 1 |
| BGB-290 Drug Profile | 34 | 2 |
| CK-102 Drug Profile | 36 | 1 |
| E-7449 Drug Profile | 37 | 1 |
| fluzoparib Drug Profile | 38 | 1 |
| niraparib Drug Profile | 39 | 4 |
| olaparib Drug Profile | 43 | 9 |
| rucaparib phosphate Drug Profile | 52 | 7 |
| Small Molecules to Target PARP1, 2, 3 and NO for Oncology Drug Profile | 59 | 1 |
| veliparib Drug Profile | 60 | 6 |
| YHP-743 Drug Profile | 66 | 1 |
| Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) Dormant Projects | 67 | 2 |
| Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) Featured News &Press Releases | 69 | 16 |
| Jul 08, 2016: ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial | 69 | 1 |
| Jul 08, 2016: Loyola Oncologist Co-authors Veliparib plus Carboplatin Study That Used New, Targeted Model to Test Breast Cancer Treatment | 70 | 1 |
| Jun 29, 2016: Myriad myChoice HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO Pivotal Phase 3 Ovarian Cancer Study with Niraparib | 71 | 1 |
| Jun 06, 2016: Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting | 72 | 3 |
| Jun 05, 2016: LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer | 75 | 1 |
| Jun 04, 2016: TESARO Provides Update on niraparib at ASCO Investor Briefing | 76 | 1 |
| Jun 04, 2016: Rucaparib shows clinical benefit in pancreatic cancer patients with BRCA mutation | 76 | 1 |
| May 31, 2016: City of Hope Presents Data on Veliparib at The American Society of Clinical Oncology s Annual Meeting | 77 | 2 |
| May 19, 2016: Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting | 79 | 1 |
| May 18, 2016: TESARO Announces Three Abstracts on Niraparib to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting | 80 | 1 |
| May 18, 2016: AstraZeneca provides top-line results from Lynparza GOLD trial in advanced gastric cancer | 80 | 1 |
| May 18, 2016: AbbVie To Present Data on Veliparib at at ASCO 2016 | 81 | 1 |
| Apr 27, 2016: Lynparzatm (Olaparib) Now Available To NHS Patients In England And Wales With BRCA-Mutated Ovarian Cancer | 82 | 1 |
| Apr 18, 2016: AstraZeneca Presents New Data On PARP Inhibitor Lynparza (olaparib) at the AACR 2016 Annual Meeting | 83 | 1 |
| Apr 14, 2016: Myriad Genetics announces presentation on niraparib study at the 2016 American Association for Cancer Research Annual Meeting | 83 | 2 |
| Appendix | 85 | 2 |
| Methodology | 85 | 1 |
| Coverage | 85 | 1 |
| Secondary Research | 85 | 1 |
| Primary Research | 85 | 1 |
| Expert Panel Validation | 85 | 1 |
| Contact Us | 85 | 1 |
| Disclaimer | 86 | 1 |